dihexa injectable peptide AngIV-Analog Dihexa Rescues Cognitive Impairment
Description
Common trial endpoints are (1) new gadolinium-enhancing T1-weighted lesions, (2) new or enlarging T2-weighted lesions, (3) annualized relapse rates, and (4) confirmed disability progression for 6 months
Pregnancy or planned pregnancy Semaglutide is contraindicated in pregnancy
Glenohumeral injections are usually performed for arthritis or frozen shoulder
Easy measuring: On a 20 mg vial, 250 mcg 4 units on a U-100 syringe
Some of these options will be relatively risk-free and lead to predictable over-par (but not too over-par) outcomes
